KR20230127372A - 브루톤 티로신 키나제 억제제의 투여 - Google Patents
브루톤 티로신 키나제 억제제의 투여 Download PDFInfo
- Publication number
- KR20230127372A KR20230127372A KR1020237028538A KR20237028538A KR20230127372A KR 20230127372 A KR20230127372 A KR 20230127372A KR 1020237028538 A KR1020237028538 A KR 1020237028538A KR 20237028538 A KR20237028538 A KR 20237028538A KR 20230127372 A KR20230127372 A KR 20230127372A
- Authority
- KR
- South Korea
- Prior art keywords
- day
- administered
- cycle
- days
- during
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944674P | 2019-12-06 | 2019-12-06 | |
| US62/944,674 | 2019-12-06 | ||
| US202063077996P | 2020-09-14 | 2020-09-14 | |
| US63/077,996 | 2020-09-14 | ||
| US202063109698P | 2020-11-04 | 2020-11-04 | |
| US63/109,698 | 2020-11-04 | ||
| PCT/US2020/063089 WO2021113497A1 (en) | 2019-12-06 | 2020-12-03 | Dosing of a bruton's tyrosine kinase inhibitor |
| KR1020227022407A KR20220100992A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227022407A Division KR20220100992A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230127372A true KR20230127372A (ko) | 2023-08-31 |
Family
ID=73854977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237028538A Pending KR20230127372A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
| KR1020227022407A Ceased KR20220100992A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227022407A Ceased KR20220100992A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12551463B2 (https=) |
| EP (1) | EP4069219A1 (https=) |
| JP (3) | JP7142173B2 (https=) |
| KR (2) | KR20230127372A (https=) |
| CN (1) | CN115175677A (https=) |
| AU (2) | AU2020397034B2 (https=) |
| BR (1) | BR112022009716A2 (https=) |
| IL (1) | IL292882A (https=) |
| MX (1) | MX2022006631A (https=) |
| WO (1) | WO2021113497A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| JP7142173B2 (ja) * | 2019-12-06 | 2022-09-26 | ロクソ オンコロジー， インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の投薬 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| KR101668574B1 (ko) | 2012-11-02 | 2016-10-24 | 화이자 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| CN114716381B (zh) | 2015-12-16 | 2025-03-11 | 洛克索肿瘤学股份有限公司 | 可用作激酶抑制剂的化合物 |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US10829488B2 (en) | 2016-08-05 | 2020-11-10 | The Regents Of The University Of Michigan | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| EP3565815B1 (en) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| EP3612531B1 (en) | 2017-04-18 | 2022-08-24 | Shanghai Fochon Pharmaceutical Co., Ltd. | Apoptosis-inducing agents |
| JP2020528061A (ja) | 2017-07-26 | 2020-09-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法 |
| KR20200108301A (ko) | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| SG11202009933WA (en) | 2018-04-29 | 2020-11-27 | Beigene Ltd | Bcl-2 INHIBITORS |
| CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| JP7142173B2 (ja) * | 2019-12-06 | 2022-09-26 | ロクソ オンコロジー， インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の投薬 |
-
2020
- 2020-12-03 JP JP2021557408A patent/JP7142173B2/ja active Active
- 2020-12-03 IL IL292882A patent/IL292882A/en unknown
- 2020-12-03 KR KR1020237028538A patent/KR20230127372A/ko active Pending
- 2020-12-03 KR KR1020227022407A patent/KR20220100992A/ko not_active Ceased
- 2020-12-03 AU AU2020397034A patent/AU2020397034B2/en active Active
- 2020-12-03 US US17/782,758 patent/US12551463B2/en active Active
- 2020-12-03 CN CN202080095816.0A patent/CN115175677A/zh active Pending
- 2020-12-03 EP EP20825385.6A patent/EP4069219A1/en active Pending
- 2020-12-03 WO PCT/US2020/063089 patent/WO2021113497A1/en not_active Ceased
- 2020-12-03 MX MX2022006631A patent/MX2022006631A/es unknown
- 2020-12-03 BR BR112022009716A patent/BR112022009716A2/pt unknown
-
2022
- 2022-09-12 JP JP2022144243A patent/JP7654604B2/ja active Active
-
2024
- 2024-02-26 AU AU2024201263A patent/AU2024201263B2/en active Active
-
2025
- 2025-03-19 JP JP2025044178A patent/JP2025098099A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020397034A1 (en) | 2022-07-21 |
| AU2024201263A1 (en) | 2024-03-14 |
| BR112022009716A2 (pt) | 2022-08-09 |
| AU2020397034B2 (en) | 2023-12-07 |
| JP2022518974A (ja) | 2022-03-17 |
| IL292882A (en) | 2022-07-01 |
| WO2021113497A1 (en) | 2021-06-10 |
| JP7654604B2 (ja) | 2025-04-01 |
| KR20220100992A (ko) | 2022-07-18 |
| EP4069219A1 (en) | 2022-10-12 |
| JP2022177119A (ja) | 2022-11-30 |
| US12551463B2 (en) | 2026-02-17 |
| NZ788615A (en) | 2024-10-25 |
| JP7142173B2 (ja) | 2022-09-26 |
| JP2025098099A (ja) | 2025-07-01 |
| MX2022006631A (es) | 2022-09-07 |
| CA3160417A1 (en) | 2021-06-10 |
| US20230041515A1 (en) | 2023-02-09 |
| AU2024201263B2 (en) | 2025-05-01 |
| CN115175677A (zh) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230107195A1 (en) | Treatment of cancer with smg1-inhibitors | |
| CN110325191A (zh) | 以较少的副作用治疗egfr-驱动的癌症 | |
| KR20180019231A (ko) | 나노입자 mTOR 억제제 조합 요법을 사용하여 혈액 악성종양을 치료하는 방법 | |
| WO2017160990A1 (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| JP2025098099A (ja) | ブルトン型チロシンキナーゼ阻害剤の投薬 | |
| EP2770830A1 (en) | Methods of treating a bruton's tyrosine kinase disease or disorder | |
| TW201822817A (zh) | HDM2-p53交互作用抑制劑之劑量及療法 | |
| JP2016522247A (ja) | 組合せ医薬 | |
| CN114246864B (zh) | Csf1r激酶抑制剂及其用途 | |
| KR20210106483A (ko) | Mdm2 억제제를 위한 확장된 저용량 요법 | |
| CN112074271A (zh) | 用于治疗淋巴瘤的方法 | |
| AU2020370110A1 (en) | Compositions comprising a DHODH inhibitor for the treatment of acute myeloid leukemia | |
| AU2020381240C1 (en) | Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies | |
| CA3160417C (en) | Dosing of a bruton's tyrosine kinase inhibitor | |
| EA046722B1 (ru) | Введение доз ингибитора тирозинкиназы брутона | |
| EA051944B1 (ru) | Введение доз ингибитора тирозинкиназы брутона | |
| NZ788615A9 (en) | Dosing of a bruton's tyrosine kinase inhibitor | |
| AU2012321091B2 (en) | Methods of treating a Bruton's Tyrosine Kinase disease or disorder | |
| JP2024503513A (ja) | がんを処置するための併用療法スケジュール | |
| KR20220063215A (ko) | 골수섬유증의 치료를 위한 mdm2 억제제의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |